Zacks Investment Research upgraded shares of Lorus Therapeutics (NASDAQ:APTO) (TSE:APS) from a hold rating to a buy rating in a research report report published on Friday morning. Zacks Investment Research currently has $3.50 target price on the biotechnology company’s stock.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
Other equities research analysts have also recently issued reports about the company. HC Wainwright restated a buy rating and set a $6.00 target price (up from $4.00) on shares of Lorus Therapeutics in a research report on Wednesday, December 13th. ValuEngine upgraded Lorus Therapeutics from a strong sell rating to a sell rating in a research report on Tuesday, March 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $5.38.
Shares of NASDAQ:APTO traded down $0.01 during trading on Friday, reaching $3.05. 117,295 shares of the company’s stock traded hands, compared to its average volume of 384,087. Lorus Therapeutics has a fifty-two week low of $0.78 and a fifty-two week high of $3.97. The stock has a market capitalization of $93.95, a PE ratio of -5.87 and a beta of 2.32.
A hedge fund recently raised its stake in Lorus Therapeutics stock. Acadian Asset Management LLC increased its holdings in shares of Lorus Therapeutics, Inc. (NASDAQ:APTO) (TSE:APS) by 316.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 44,421 shares of the biotechnology company’s stock after acquiring an additional 33,766 shares during the period. Acadian Asset Management LLC owned approximately 0.17% of Lorus Therapeutics worth $100,000 as of its most recent SEC filing. Institutional investors own 1.23% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades Lorus Therapeutics (APTO) to “Buy”” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/zacks-investment-research-upgrades-lorus-therapeutics-apto-to-buy.html.
About Lorus Therapeutics
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Get a free copy of the Zacks research report on Lorus Therapeutics (APTO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lorus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lorus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.